Bayer AG and Meituan Deepen Partnership to Transform Skin Health Market in China
CompanyDeals

Bayer AG and Meituan Deepen Partnership to Transform Skin Health Market in China

Changchun High & New Technology Industries Receives FDA Tacit Approval for GenSci122 Clinical Study
CompanyDrug

Changchun High & New Technology Industries Receives FDA Tacit Approval for GenSci122 Clinical Study

Jiangsu Hengrui Medicine Co., Ltd (600276.SH), a leading pharmaceutical company in China, has announced that it has received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) for its modified drug HR19042, which targets active autoimmune hepatitis (AIH).
CompanyDrug

Jiangsu Hengrui’s HR19042 Earns Breakthrough Designation for Autoimmune Hepatitis Treatment in China

Eli Lilly’s Mirikizumab Shows Statistically Significant Improvement in Crohn's Disease VIVID-1 Study
CompanyDrug

Eli Lilly’s Mirikizumab Shows Statistically Significant Improvement in Crohn’s Disease VIVID-1 Study

Humanwell Healthcare Secures NMPA Approval for Clinical Trial of HW211026 to Treat Actinic Keratosis
CompanyDrug

Humanwell Healthcare Secures NMPA Approval for Clinical Trial of HW211026 to Treat Actinic Keratosis

Thermo Fisher Faces FDA Scrutiny Over Syringe Air Bubble Protocols at North Carolina Plant
Company

Thermo Fisher Faces FDA Scrutiny Over Syringe Air Bubble Protocols at North Carolina Plant

United Laboratories' TUL12101 Eye Drops Enter Phase IIa Clinical Trial for Dry Eye Syndrome
CompanyDrug

United Laboratories’ TUL12101 Eye Drops Enter Phase IIa Clinical Trial for Dry Eye Syndrome

3D Medicines' Envafolimab Earns NMPA Breakthrough Designation for TMB-H Solid Tumors
CompanyDrug

3D Medicines’ Envafolimab Earns NMPA Breakthrough Designation for TMB-H Solid Tumors

Roche's Vabysmo Receives NMPA Approval for Macular Edema Treatments in China
CompanyDrug

Roche’s Vabysmo Receives NMPA Approval for Macular Edema Treatments in China

Intas Pharmaceuticals Receives FDA Approval for Biosimilar Stelara, Expanding Treatment Options for Autoimmune Diseases
CompanyDrug

Intas Pharmaceuticals Receives FDA Approval for Biosimilar Stelara, Expanding Treatment Options for Autoimmune Diseases

Beijing Aims to Build a Leading Cell and Gene Therapy Hub by 2026 with New Action Plan
Policy / Regulatory

Beijing Aims to Build a Leading Cell and Gene Therapy Hub by 2026 with New Action Plan

RemeGen's Disitamab Vedotin Receives Priority Review for New Indication in Breast Cancer by China's NMPA
CompanyDrug

RemeGen’s Disitamab Vedotin Receives Priority Review for New Indication in Breast Cancer by China’s NMPA